Combining neural stem cells and a protein to treat ischemic stroke
Official title: Combination treatment of ischemic stroke with perlecan DV and neural stem cells
Funded at University of California Riverside · NIH-10915844 · Data updated 2026-11-12
This study is looking at a new way to help people recover from ischemic stroke by using special cells and a protein to protect the brain, and it aims to see if this treatment can improve recovery and brain health after a stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | June 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $305,122 |
| NIH project number | 7R01NS110370-06 |
| Project ID | NIH-10915844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently experienced an ischemic stroke and are within the sub-acute phase of recovery.
✕Less likely to help
Patients who have had a stroke for an extended period or those with other severe comorbidities may not benefit from this research.
What this research studies
This research investigates a new treatment approach for ischemic stroke by using neural stem cells (NSCs) and a protein fragment called perlecan domain V (DV). The goal is to administer NSCs during the sub-acute phase of stroke to protect the blood-brain barrier from damage caused by ischemia-reperfusion injury. The researchers have shown promising results in animal models, indicating that this combination therapy could improve neurological function and reduce damage to the brain. Patients may be monitored for improvements in recovery and overall brain health.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery outcomes for stroke patients by minimizing brain damage and enhancing neurological function.
How similar studies have gone: Previous research has shown success with similar approaches using stem cells for stroke treatment, but this specific combination is novel.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Lee, Jean-Pyo — University of California Riverside
- Study coordinator: Lee, Jean-Pyo
Related research
Other NIH-funded projects on the same topics.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
Genetic testing to find causes of early-onset ischemic stroke
This project uses whole-exome sequencing to look for gene changes that may cause ischemic stroke in adults who had a stroke at a young age.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
How biological aging and blood proteins relate to thinking after a stroke
This project looks at whether measures of biological aging and patterns of blood proteins help explain which stroke survivors keep their thinking sharp and which go on to develop vascular dementia.
-
Repurposing NEXLETOL to treat ischemic stroke
Aims to see if the cholesterol drug NEXLETOL can help people after an ischemic stroke by supporting brain energy use and reducing injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.